Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer.
Ghosh J, Joy Phillip DS, Ghosh J, Bajpai J, Gulia S, Parmar V, Nair N, Joshi S, Sarin R, Budrukkar AN, Wadasadawala T, Desai SB, Shet T, Patil A, Sawant SP, Dhir AA, Kembhavi S, Popat P, Hawaldar R, Kembhavi Y, Perumal P, Banavali SD, Badwe RA, Gupta S.
Ghosh J, et al. Among authors: kembhavi y.
Indian J Cancer. 2022 Jul-Sep;59(3):387-393. doi: 10.4103/ijc.IJC_850_19.
Indian J Cancer. 2022.
PMID: 33753616
Free article.
Clinical Trial.